These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 9049482)

  • 21. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
    Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
    Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
    Uçkaya G; Delagrange P; Chavanieu A; Grassy G; Berthault MF; Ktorza A; Cerasi E; Leibowitz G; Kaiser N
    J Endocrinol; 2005 Mar; 184(3):505-13. PubMed ID: 15749809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
    Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
    J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
    Toft-Nielsen M; Madsbad S; Holst JJ
    Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
    Zander M; Madsbad S; Madsen JL; Holst JJ
    Lancet; 2002 Mar; 359(9309):824-30. PubMed ID: 11897280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Glucagon-like peptide-1(GLP-1)].
    Wasada T
    Nihon Rinsho; 2004 Jun; 62(6):1175-80. PubMed ID: 15206160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
    Nyström T; Gutniak MK; Zhang Q; Zhang F; Holst JJ; Ahrén B; Sjöholm A
    Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1209-15. PubMed ID: 15353407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
    Byrne MM; Göke B
    Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
    Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
    Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
    Juntti-Berggren L; Pigon J; Karpe F; Hamsten A; Gutniak M; Vignati L; Efendic S
    Diabetes Care; 1996 Nov; 19(11):1200-6. PubMed ID: 8908380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL; Holst JJ; Vølund A; Madsbad S
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
    Ahrén B; Holst JJ; Mari A
    Diabetes Care; 2003 Oct; 26(10):2860-4. PubMed ID: 14514592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.